青光眼滴眼液无反应者识别新路径的可接受性、依从性与经济学分析
这是一项单臂非随机前瞻性观察研究,纳入新诊断青光眼或高眼压患者,评估「卡迪夫青光眼诊疗模型」的可接受性、临床反应性与依从性,并进行经济学分析。72 名受邀患者中 53 人入组(74.3%),50 人完成全部流程(94.3%);最终访视时 92 只研究眼中有 83 只眼压下降超过 15%(90.2%),在尽量排除低依从影响后无反应率为 5.1%。该路径成本极小、患者可接受,但医护人员认为 4 小时与 4 周随访预约可能带来管理问题。
要点
- 该路径在边际成本下提供新的临床与依从性信息,患者可接受。
- 最终访视时 90.2% 研究眼眼压下降超过 15%,无反应率 5.1%。
- 医护人员对 4 小时与 4 周随访预约的可行性存在分歧。
核心结论
- 卡迪夫青光眼诊疗模型以极小成本提供新的临床与依从性信息,且患者可接受,但医护人员接受度存在差异,4 小时与 4 周随访预约可能造成管理问题。
研究设计与样本
- 单臂非随机前瞻性观察研究,纳入新诊断青光眼/高眼压患者,采用定性观察与访谈评估可接受性。
- 在两次不同预约中分别于临床医生滴药前及滴药后 4 小时测量眼压以判定临床反应性,并使用药物事件监测系统(MEMS)收集依从性数据。
- 经济学分析比较新路径与标准诊疗路径的成本,试验注册号 ISRCTN75888393。
主要发现
- 72 名受邀患者中 53 人入组(74.3%),50 人完成全部流程(94.3%)。
- 最终访视时 92 只研究眼中 83 只眼压下降超过 15%(90.2%)。
- 在尽量减小低依从影响后,无反应率为 5.1%。
- 观察期内共 1376 个滴药日,按处方滴药 1004 天(73.0%),过量滴药 137 天(9.9%),未滴药 235 天(17.1%)。
关键数值与推荐
- 眼压反应判定标准为滴药后较滴药前下降超过 15%。
- 无反应率 5.1% 为尽量减小低依从影响后的结果。
- 观察期滴药依从构成:按处方滴药 73.0%、过量滴药 9.9%、未滴药 17.1%。
临床怎么用
- 可考虑采用该路径在边际成本下同时获取眼压反应性与依从性信息。
- 对 4 小时与 4 周随访预约需评估行政可行性,研究团队已开发简化版路径以促进临床采纳。
局限性
- 单臂非随机设计,无对照组。
- 样本量较小(入组 53 人、完成 50 人)。
- 医护人员对路径接受度存在差异,随访安排可能影响推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Assess whether a new clinical pathway for glaucoma was acceptable to patients and healthcare professionals and whether it provided useful clinical information on non-responsiveness and non-adherence to the treatment of elevated intraocular pressure with latanoprost eye drops. METHODS: A single arm non-randomised prospective observational study incorporating new glaucoma/ocular hypertension patients. To assess issues of acceptability, qualitative observation and interviews were conducted with patients and healthcare professionals. To determine clinical responsiveness, intraocular pressures were measured before and 4 hours after a clinician-instilled eye drop over two distinct appointments. Adherence data were collected using a Medicine Event Monitoring System. Economic analyses compared the costs between novel and standard care pathways. RESULTS: Of 72 patients approached, 53 entered the study (74.3%) and 50 completed all procedures (94.3%). Intraocular pressure was reduced more than 15% in 83 out of 92 study eyes by final visit (90.2%). The non-response rate was 5.1% once the effect of low adherence was minimised. For the 1376 drop instillation days under observation, eye drops were instilled as prescribed on 1004 days (73.0%), over-instilled on 137 days (9.9%) and not instilled on 235 days (17.1%). The Cardiff Model of Glaucoma Care involved negligible cost, although acceptance for healthcare professionals showed variation. CONCLUSIONS: The Cardiff Model of Glaucoma Care offers novel clinical and adherence insights at marginal costs while acceptable to patients. Healthcare professionals felt that 4 hour and 4 week follow-up appointments could cause administrative problems. A streamlined version of the pathway has therefore been developed to facilitate clinical adoption. TRIAL REGISTRATION NUMBER: ISRCTNID:ISRCTN75888393.
引用
- Waterman H, Read S, Morgan JE, et al. Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study. Br J Ophthalmol. 2020. PMID: 32139500. doi:10.1136/bjophthalmol-2019-315436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。